Pemetrexed in the treatment of selected solid tumors

被引:9
作者
Adjei, AA
机构
[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Div Oncol, Rochester, MN USA
关键词
D O I
10.1053/sonc.2002.30758
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:50 / 53
页数:4
相关论文
共 18 条
[1]   Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors [J].
Adjei, AA ;
Erlichman, C ;
Sloan, JA ;
Reid, JM ;
Pitot, HC ;
Goldberg, RM ;
Peethambaram, P ;
Atherton, P ;
Hanson, LJ ;
Alberts, SR ;
Jett, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) :1748-1757
[2]   Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors [J].
Adjei, AA .
ANNALS OF ONCOLOGY, 2000, 11 (10) :1335-1341
[3]   MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin [J].
Calvert, AH ;
Hughes, AN ;
Calvert, PM ;
Plummer, RE ;
Highley, MS .
EUROPEAN JOURNAL OF CANCER, 1999, 35 :S285-S286
[4]  
CALVERT AH, 1998, BRIT J CANCER, V3, P34
[5]  
GOEDHALS L, 1998, ANN ONCOL, V9, P339
[6]  
GREM JL, 1990, CANC CHEMOTHERAPY PR, P180
[7]  
GRINDEY G B, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P411
[8]  
O'Dwyer PJ, 1999, SEMIN ONCOL, V26, P99
[9]  
PAZARES L, 1998, P AN M AM SOC CLIN, V17, pA339
[10]  
Pivot X, 1999, P AN M AM SOC CLIN, V18, p397a